Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + vinorelbine + doxorubicin liposome + rituximab
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of gemcitabine (a nucleoside analog), vinorelbine (a vinca alkaloid), liposomal doxorubicin (an anthracycline in a liposomal formulation), and rituximab (an anti-CD20 monoclonal antibody). This regimen is primarily used as a salvage therapy for patients with relapsed or refractory lymphomas, particularly non-Hodgkin lymphoma and Hodgkin's lymphoma. The typical dosing regimen varies, but often includes Gemcitabine (800-1000 mg/m²), Vinorelbine (20-25 mg/m²), Liposomal Doxorubicin (15 mg/m²), and Rituximab (375 mg/m²), administered in cycles.
- Other names
- GVD-R
02
Targets
Beyond the preview
Go deeper on gemcitabine + vinorelbine + doxorubicin liposome + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + vinorelbine + doxorubicin liposome + rituximab.